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Abstract
Background: There are few large published studies of HIV controllers with long-term undetectable viral load (VL). We
describe the characteristics and outcomes of 81 French HIV controllers.
Methods and Results: HIV controllers were defined as asymptomatic, antiretroviral-naı ¨ve persons infected $10 years
previously, with HIV-RNA ,400 copies/mL in .90% of plasma samples. All available CD4 and VL values were collected at
enrolment. Mixed-effect linear models were used to analyze CD4 cell count slopes since diagnosis. HIV controllers
represented 0.31% of all patients managed in French hospitals. Patients infected through intravenous drug use were
overrepresented (31%) and homosexual men were underrepresented (26% of men) relative to the ANRS SEROCO cohort of
subjects diagnosed during the same period. HIV controllers whose VL values were always below the detection limit of the
assays were compared with those who had rare ‘‘blips’’ (,50% of VL values above the detection limit) or frequent blips
(.50% of VL values above the detection limit). Estimated CD4 cell counts at HIV diagnosis were similar in the three groups.
CD4 cell counts remained stable after HIV diagnosis in the ‘‘no blip’’ group, while they fell significantly in the two other
groups (20.26!CD4 and 20.28!CD4/mm
3/year in the rare and frequent blip groups, respectively). No clinical,
immunological or virological progression was observed in the no blip group, while 3 immunological and/or virological
events and 4 cancers were observed in the blip subgroups.
Conclusions: Viral blips in HIV controllers are associated with a significant decline in CD4 T cells and may be associated with
an increased risk of pathological events, possibly owing to chronic inflammation/immune activation.
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Introduction
So-called HIV controllers (HIC) are individuals in whom HIV-1
remains undetectable without antiretroviral treatment, regardless
of the CD4 cell count [1–5]. These patients differ from long-term
non progressors (LTNP) [6–10], who are defined as having high
and stable CD4 cell counts (.500 or 600/mm
3). Seven to eight
percent of untreated HIV-1 seroconverters have undetectable viral
load on two consecutive occasions during the first years following
infection [11,12]. HIV controllers, who have durably undetectable
viral load, are rarer, representing less than 1% of routinely
monitored patients [13–14]. A better understanding of the
mechanisms responsible for spontaneous sustained HIV control
could assist with the development of vaccines and new therapies.
Most studies of HIV controllers have focused on pathophysiolog-
ical aspects, while few data are available on clinical and
sociodemographic characteristics or long-term CD4 cell count
dynamics after HIV diagnosis [15]. We describe the epidemiologic
characteristics and disease outcomes of 81 HIV controllers
recruited in 2006–2007 by the ANRS HIV Controllers French
National Observatory.
Methods
With their written informed consent, HIV controllers identified
among HIV-1-infected patients managed in 35 clinical centers in
France were enrolled in the ANRS EP36 national program in
2006–2007. They had to have had untreated asymptomatic HIV-1
infection for more than 10 years and plasma HIV-1 RNA levels
below 400 copies/ml in more than 90% of samples tested since
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e18726diagnosis. All previous CD4 T cell counts and plasma HIV-1 RNA
values were collected at enrolment, as well as demographic,
epidemiological and clinical data. CD4 cell counts were routinely
determined by flow cytometry using standard procedures. Plasma
HIV-RNA was measured with the Cobas Amplicor HIV Monitor
in 69% of samples [Roche Molecular Systems, Neuilly sur Seine,
France; detection limit 500 to 20 copies/mL]; the Quantiplex
HIV-RNA (bDNA) assay [Bayer Diagnostics, Puteaux, France;
detection limit 10 000 to 40 copies/mL] in 27% of samples; and
other techniques in 4% of samples [detection limits 500 to 40
copies/mL]. Whole-blood samples were also cryopreserved at
enrolment, for HIV DNA assay by a centralized laboratory using
the ANRS real-time PCR assay [16]. Samples with very low values
were tested in quadruplicate by PCR in order to obtain numerical
data. Results were expressed as log10 copies per million PBMC.
The patients were divided into three groups on the basis of their
viral load values since HIV diagnosis: 1) a ‘‘no blip’’ group (n=30)
with plasma HIV-RNA always below the detection limit (including
in assays with a sensitivity of 50 copies/ml in recent years); 2) a
‘‘rare blips’’ group (n=39), in which fewer than 50% of HIV-
RNA values were above the detection limit; and 3) a ‘‘frequent
blips’’ group (n=12) in which more than 50% of HIV-RNA values
were above the detection limit. In keeping with the definition of
HIV controllers, at least 90% of viral load values in these latter
two groups were nonetheless below 400 copies/mL.
Continuous variables were expressed as the median and inter-
quartile range [IQR] or range, and qualitative variables as the
frequency (n) and percentage (%). Continuous variables were
compared with the Kruskall Wallis test and qualitative variables
with the Pearson chi-square test or Fisher’s exact test. Univariate
and multivariate (after adjustment for sex, age and ethnicity)
mixed-effect linear models were used to estimate changes in CD4
cell counts over time. This model was used in order to take into
account the fact that the subjects had repeated CD4 measure-
ments. Square root transformation of CD4 cell counts was used to
fulfill the model assumptions. The SAS (Version 9.1, 2003; SAS
Institute Inc., Cary, NC, USA) and STATA programs (Version
11.0, 2009; Stata Corp., College Station, Texas) were used for
statistical analysis.
Results
Characteristics of HIV controllers
Among 34 317 patients managed in 35 French clinical centers,
106 HIV controllers were identified (0.31%; 95%CI [0.25%–
0.37%]) and 81 of them agreed to participate in this study. Thirty-
five (43%) of these 81 patients were women, 68 (84%) were
Caucasian, 85% defined themselves as heterosexuals (100% of
women and 74% of men), and 26% of the men defined themselves
as homo-bisexual. Median age at HIV diagnosis was 29 years
[range: 0.8–64] and median age at enrollment in this study was 45
years [range: 19–78]. HIV infection was attributed to sexual
intercourse in 42 cases (52%), intravenous drug use in 25 cases
(31%), blood transfusion in 3 cases; exposure to blood products for
hemophilia in 3 cases; and mother-child transmission in 1 case; the
route of infection was unknown in 7 cases. The median year of
HIV diagnosis was 1989 [IQR: 1987–1994], and the median time
from diagnosis to enrollment in the HIV controllers study was 17
years [IQR: 13–19].
These patients’ baseline characteristics were then compared
with those of the patients enrolled in the ANRS SEROCO cohort
[17,18], consisting of HIV-infected subjects diagnosed during the
same calendar period and still alive in 2007 (table 1). The
proportion of women tended to be higher among HIV controllers
than in the SEROCO cohort (p=0.06) but this trend disappeared
after adjustment for ethnicity. Among men, the proportion of
homo-bisexuals was much lower among HIV controllers than in
the SEROCO cohort (26.1% vs. 54.3%; p,0.001). The
proportion of intravenous drug users was higher among HIV
controllers than in the SEROCO cohort. These last two
Table 1. Comparison of baseline characteristics between HIV controllers and patients enrolled in the ANRS SEROCO Cohort and
still alive in 2007.
Characteristics
SEROCO Cohort Study
N=528
HIV Controllers Study
N=81 p
Women 168 (32.5) 35 (43.2) 0.06
Sexual pref. among men (n=357) (n=46)
Heterosexual 163 (45.7) 34 (73.9)
Homosexual 194 (54.3) 12 (26.1) ,0.001
Caucasians 496 (93.9) 68 (83.8)
SSA/C* 21 (4.0) 13 (16.2) ,0.001
Others 11 (2.1) 0 (0.0)
Transmission group
Sexual 342 (64.8) 42 (51.9)
IVDU 40 (7.6) 25 (30.9) ,0.001
Others 146 (27.6) 14 (17.2)
Year of HIV diagnosis 1989 [1988–1990] 1989 [1987–1994] 0.003
Age at HIV diagnosis 27 [23–34] 29 [24–32] 0.27
First CD4**/mm
3 520 [357–682] 795 [627–1000] ,0.001
First viral load** (% , threshold) 20 (4.3) 65 (80.3) ,0.001
Data are median [IQR] or n (%);
*SSA/C = SubSaharan Africans or Caribbeans;
**Following HIV diagnosis.
doi:10.1371/journal.pone.0018726.t001
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cell counts at HIV diagnosis were higher in HIV controllers than
in the SEROCO cohort (median 795 vs. 520 CD4/mm
3,
p,0.001) and percentage of undetectable viral load observed on
the first available load was lower in the SEROCO cohort than in
HIV controllers (4.3% vs. 80.3%, p,0.001).
Asexpected,theHLA-B57 andB27alleles wereover-represented
among HIV controllers (respectively 45% and 15% of Caucasian
controllers) when compared to the French Caucasian general
population (6.2% and 6.9%, respectively; www.allelefrequencies.
net).
Viral load and CD4+ T cell counts in HIV controllers
All available HIV-RNA and CD4 T cell values since HIV
diagnosis were collected. The detection limits of viral load assays
improved over time: in 1996-99, 36.8% of viral loads were
measured with assays having detection limits below 50 copies/ml,
compared to 83.0% in 2000–2004 and 95.9% after 2005. As the
median year of HIV diagnosis was 1989, the first viral load
measurement in the HIV controllers took place a median of 6.9
years [IQR: 3.5–10.0] after HIV diagnosis. Among these first
measurements, 80.3% were below the detection limit (range of the
detection limits: 20 to 10 000 copies/ml). Viral load was detectable
in the first measurement in 16 patients but the levels were low
(median 303 copies/mL; range 84 to 2200 copies/mL), and the
time to first undetectable VL was rather short: the median time
between HIV diagnosis and the first sample with ‘‘undetectable’’
viral load in these 16 patients was only 17.7 [9.2–38.6] months.
Four of these 16 patients were known to have had a negative Elisa
HIV screening test (the median interval between the last negative
serology and the first positive serology was 9.3 [6.2–18.0] months).
The first CD4 T cell count was recorded a median of 2.1 years
[IQR: 0.1–5.9] after HIV diagnosis and the median value was
795/mm
3 [IQR: 627–1000]. The median of all CD4 T cell counts
recorded since HIV diagnosis was 777/mm
3 [IQR: 599–980];
14% of values were ,500/mm
3, 3% were ,350/mm
3 and 4 were
,200/mm
3 (once in one patient, and three non consecutive assays
in another patient).
At enrollment in the HIV controllers study the median CD4 cell
count was 741/mm
3 [IQR: 521–937]; it was below 500/mm
3 in
22% of patients and below 350 in 5%; VL was below 400 copies/
ml in 96.3% of patients and below the detection limit of 50 copies/
mL in 74.1% of patients. Among patients who were enrolled with
viral load above the detection limit (n=22), the median VL was
132 copies/mL [range: 43–1443]. Cellular HIV DNA was
quantified in 53 patients at enrolment, and the median value
Table 2. Main characteristics of HIV controllers according to blip status during follow-up.
Characteristics
No Blips
N=30
Rare Blips
N=39
Frequent Blips
N=12 p
Women 15 (50.0) 14 (35.9) 6 (50.0) 0.44
Caucasians 23 (76.7) 34 (87.2) 11 (91.7) 0.45
Heterosexual preference 26 (86.7) 31 (79.5) 12 (100.0) 0.25
MSM among men (n=46) 4/15 (26.7) 8/25 (32.0) 0/6 (0.0) 0.38
Intravenous drug users 11 (36.7) 11 (28.2) 3 (25.0) 0.76
Year of diagnosis 1991 [1988–1994] 1989 [1987–1994] 1988 [1987–1989] 0.08
Year of inclusion 2007 [2006–2007] 2006 [2006–2007] 2006 [2006–2007] 0.09
Age at diagnosis, years 28 [26–32] 29 [23–33] 28 [24–35] 0.89
Age at inclusion, years 45 [40–49] 45 [39–49] 48 [42–50] 0.56
Number of HIV-RNA measurements 14 [9–19] 17 [14–22] 17 [11–19] 0.09
Number of HIV-RNA measurements/year since 1
st VL (mean(std)) 1.8 (0.8) 1.9 (0.6) 1.9 (0.6) 0.81
Number of blips (HIV-RNA .detection limit*) 0 [0-0] 4 [2–6] 11 [9–14] ,0.001
% of blips (HIV-RNA .detection limit) 0.0 [0.0–0.0] 23.5 [14.3–29.4] 75.0 [67.9–83.3] ,0.001
% blips .400 copies/mL 0.0 [0.0–0.0] 15.0 [0.09–0.21] 12.4 [0.07–0.18] 0.53
At first measurement** 14 (35.9)
First CD4 measurement,/mm
3 2.8 [0.3 1.3 [0.01 3.0 [0.1 0.16
Time from HIV diagnosis to first HIV-RNA measurement, years 813 [610 795 [641 782 [624 0.73
Time from HIV diagnosis to first CD4 measurement, years 5.9 [3.0 7.8 [2.9 9.7 [7.4 0.11
At inclusion in the HIV controllers study
Time since HIV diagnosis, years 15.1 [11.9–19.1] 16.9 [13.9–19.1] 18.5 [17.2–20.3] 0.13
Time since 1
st viral load, years 8.7 [7.0–9.8] 9.7 [8.8–10.7] 9.5 [8.6–9.9] 0.03
CD4 T cell counts,/mm
3 819 [668–992] 644 [445–890] 628 [569–906] 0.02
HIV-DNA, log10 copies/million PBMC 1.78 [1.34–2.18] 1.70 [1.45–2.00] 1.90 [1.62–2.09] 0.73
HIV-RNA .400 copies/mL 0 (0.0) 1 (2.7) 2 (18.3) 0.06
Cancer during follow-up 0 (0.0) 3 (7.7) 1 (8.3) 0.26
Data are median [IQR], mean (std) or n (%);
*whatever the precise detection limit;
**First measurement available after HIV-1 diagnosis.
doi:10.1371/journal.pone.0018726.t002
CD4 Dynamics among HIV Controllers
PLoS ONE | www.plosone.org 3 April 2011 | Volume 6 | Issue 4 | e18726was 1.74 log copies/million PBMC [IQR: 1.36–2.07]. The virus
was subtype B in 93% of cases.
CD4 cell kinetics since HIV diagnosis
The patients were divided into three groups on the basis of their
viral load history since HIV diagnosis, as follows: patients who were
always below the detection limit (n=30; ‘‘no blip’’ group), patients
in whom fewer than 50% of VL values were above the detection
limit (n=39; ‘‘rare blip’’ group), and patients in whom more than
50% of VL values were above the detection limit (n=12; ‘‘frequent
blip’’ group).Themean numberof VLmeasurements/yearsince1
st
VL measurement was similar in the three groups (table 2); the mean
delay between two VL measurements was also similar: 7.3 months,
6.7 months and 7.2 months in the no, rare and frequent groups,
respectively, p=0.48. The proportion of assays with a detection
limit of #50 copies/mL was not lower in the no blip group (74.7%)
than in the rare and frequent blip groups (69.8% and 80.3%
respectively). In the rare and frequent blip groups only 15.0% and
12.4% of blips exceeded 400 copies/mL, and the median
magnitude of the blips did not differ between these 2 groups (115
copies/mL [range: 25–52000] and 152 copies/mL [range: 30–
7500] respectively, p=0.32). The median interval between the first
viral load measurement and the first blip was 30.5 months [IQR:
3.7–61.2] in the rare blip group and 4.3 months [IQR: 0.0–19.9] in
the frequent blip group (p=0.007). Clusters of blips were, by
definition, more frequent in the frequent group than in the rare blip
group. However, most of the blips were transient, i.e., they were
followed by a VL below the detection level.
Table 2 describes the main characteristics of these three
subgroups. No difference was found in terms of sex, age or the
firstCD4cellcountfollowingHIVdiagnosis.However,atenrolment
in this study the median CD4 T cell count was significantly higher in
the no blip group (p=0.02) than in the other two groups, while the
median HIV-DNA level was similar in the three groups.
In order to better analyze the CD4 cell count kinetics, we
estimated the slopes of square-root CD4 T-cell counts by using a
mixed-effects linear model. In the no blip group (30 patients), 508
values were used to estimate the slope, with an average of 16 points
[range: 6–34] per patient. The corresponding figures were 885
values and 23 points per patient (range: 16–40) in the rare blip
group, and 275 values and 22 points per patient (range: 5–47) in the
frequent blip group. Overall, the estimated intercept (i.e. the
estimated mean CD4 cell count at HIV diagnosis) was 30!CD4/
mm
3 (i.e. 900 CD4) and the slope was -0.17!CD4/mm
3/year. In
other words, during the first year of infection, the CD4 cell count in
an HIV controller with 900 CD4 cells/ml at HIV diagnosis fell to
890 CD4/mm
3 [95%CI: 885.0–899.4], representing a mean
decline of 10 CD4/mm
3. The mean intercept did not differ across
the three groups: it was 29.5!CD4/mm
3 [95%CI: 27.4–31.5] in the
no blip group, 29.9!CD4/mm
3 [25.2–34.6] in the rare blip group
and 30.6!CD4/mm
3 [27.8–36.4] in the frequent blip group. The
slope in the no blip group did not differ from zero: +0.01!CD4/
mm
3 per year [95%CI: 20.13; +0.15] (p=0.89). In contrast, CD4
cell counts in the rare and frequent blip groups fell significantly over
time: respectively 20.25 !CD4/mm
3 per year [95%CI: 20.08;
20.43; p=0.005], and 20.28 !CD4/mm
3 per year [95%CI:
Figure 1. Predicted trajectories of mean !CD4 cell counts since HIV diagnosis according to blip status during the period of HIV
control (81 HIV controllers, 1668 CD4 measurements).
doi:10.1371/journal.pone.0018726.g001
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from that of the no blipgroup, butnot from eachother. Fig. 1 shows
the predicted trajectories of mean !CD4 cell counts in the three
groups. The results were similar in a more global model that
included sex, ethnicity, age at diagnosis (dichotomized around the
median of 29 years) and interaction terms between the time since
HIV-1 diagnosis and the group. As the rare and frequent blip
groups had similar intercepts and slopes, we estimated the slope in
all patients with blips: 20.26!CD4/mm
3 per year [95%CI: 20.09;
20.43; p=0.003]. This corresponds to a fall in the CD4 cell count
from 903 CD4/mm
3 [95% CI: 818–992] at HIV diagnosis to 830
CD4/mm
3 [762–901] five years later, 760 CD4/mm
3 [700–822]
10 years later, and 629 CD4/mm
3 [558–704] 20 years later.
We also conducted a supplementary analysis by restricting the
definition of blips to those occurring in the last five years, i.e. when
all the patients had their VL measured with an assay with a cut-off
for detection #50 copies/mL. We could therefore define the no
blips group more homogenously by patients having always in the
last five years of their follow-up their VL below 50 copies. We found
that CD4 behaved differently in patients with viral load always #50
copies/mL (no blips group) from patients with blips .50 copies.
CD4 slopes in patients with blips within 50–400 copies and patients
with blips .400 copies did not differ significantly (figure 2).
Post-enrolment outcomes
After inclusion in the HIV controllers study, 3 patients
experienced immunological HIV disease progression, consisting
of a strong and sustained decrease in the CD4 cell count to
below 200/mm
3; one of these patients also had a sustained
increase in viral load above 1000 copies/mL. Four patients,
including one of the patients in whom the CD4 cell count fell
below 200/mm
3, developed cancer (B cell lymphoma, lung
adenocarcinoma, non-differentiated hepatic carcinoma, and
gastrointestinal malignancy), and two patients died, one from
cardiovascular disease and one from an unknown cause. All
three controllers who experienced immunological progression
after enrolment belonged to one of the two blip groups, as did
the four patients with cancer. The last CD4 cell counts before
cancer diagnosis were 225, 521, 977 and 680/mm
3.N o
immunological or virological escape or clinical progression was
observed in the no blip group.
Discussion
Spontaneous viral control shortly after HIV-1 seroconversion is
not uncommon. Among 330 seroconverters from the ANRS
SEROCO cohort, we previously found that 4% of patients had
HIV-RNA ,400 copies/mL during the 6–24 months following
infection, while only one patient had HIV-RNA ,40 copies/mL
[19]. In the European CASCADE collaboration, spontaneous
virological control, defined by at least two consecutive viral loads
below the detection limit (,400/500 copies/mL), occurred in 7%
of recently infected patients [11]. Long-lasting spontaneous control
of viremia is far more rare: here, among 34 317 HIV-seropositive
patients managed in 2008 in the 35 French clinical sites
participating in the HIV Controllers Observatory, we found that
Figure 2. Predicted trajectories of mean !CD4 cell counts since HIV diagnosis according to blip status in the last five years of
control (always #50 copies vs. blips within 50–400 and blips .400 copies/mL) (81 HIV controllers, 1668 CD4 measurements).
doi:10.1371/journal.pone.0018726.g002
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described in other studies (13, 20).
The factors responsible for HIV control are unclear [4,21]. As
generally reported, we observed a higher proportion of women
than men among HIV controllers. However, women were no
longer significantly over-represented after adjustment for ethnicity
(Africans vs others). In a recent study [15], 100% of natural viral
suppressors were African-Americans, who represented 85% of the
entire cohort (n=2484). Our findings suggest that any influence of
gender on sustained HIV control might be partly explained by
ethnicity.
Relative to the French ANRS SEROCO cohort, homosexual
men were under-represented among male HIV controllers in
our study, while intravenous drug users were over-represented.
Grabar et al. obtained similar results when comparing HIV
controllers with other untreated patients [20]. There is no clear
explanation for this finding but it is conceivable that homose-
xual men, as a group, may be treated earlier than drug users,
making them ineligible for identification as HIV controllers.
It is striking to note that median year of HIV diagnosis in
these HIV controllers was 1988 in intravenous drug users and
1992 in homosexual men. We cannot either exclude that
the route of infection might play a role. Finally, we also con-
firm here that HIV controllers have very low levels of cellular
HIV-DNA [21].
In the general population of HIV-1-infected patients, the CD4
T cell count declines by 60 to .100 cells/mm
3 per year [12,22–
25]. In a population of long-term nonprogressors (LTNP), the
estimated CD4 T cell count decline was 32/mm
3 per year in
patients aged less than 25 years at HIV diagnosis and 16 cells/
mm
3 per year in older patients [10]. In our population of HIV
controllers the CD4 cell count decline was much slower, at an
estimated 10 cells/mm
3 per year. The group with highly
sustained viral control showed no CD4 T cell decline, whereas
the groups with blips had a slight but significant decline over
time (approximately 15 CD4/mm
3 during the first year of HIV
infection). This confirms, over a much longer period, findings
from a recent study [26] in which the slope of the CD4 cell
count differed between controllers with VL ,1 copy/mL and
those with persistent low-level viremia $1 copy/mL. In another
study we found that 19 HIV controllers from the Observatory
fell into two groups with respect to the HIV-suppressive capacity
of their CD8 T cells and their HIV-specific CD8 T cell numbers:
14 patients had a high frequency of HIV-specific CD8 T cells
with marked and stable HIV-suppressive capacity and higher
levels of T cell activation, while the other five patients had very
weak HIV-specific responses and immune activation [27]. These
latter five patients with weak responses had experienced no VL
blips, while 11 of the 14 patients with strong CD8+ Tc e l l
responses had had blips. Thus, in keeping with recent data
[28,29], low-level viremia might be important for sustaining an
effective CD8+ T cell response, but the price might be a faster
CD4+ T cell decline and an increased risk of virologic failure
and clinical events. Interestingly, the three controllers who
experienced CD4 T cell declines below 200/mm
3 and the four
patients who developed cancer had all experienced blips.
Malignancies in blip patients might be related to chronic
immune activation and/or inflammation [30]. Thus, HIV
controllers who experienced viral blips and/or chronic immune
activation [31,32], might be more at risk of malignancies and
thus require closer follow-up. We are currently implementing a
prospective cohort of HIV controllers designed to determine the
long-term prognosis, including changes in the CD4 cell count
and viral load, and the risk of cancer.
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